Enalaprilat  (Synonyms: MK-422 anhydrous)

Enalaprilat (MK-422 anhydrous), the active metabolite of the oral proagent Enalapril, is a potent, competitive and long-acting angiotensin-converting enzyme (ACE) inhibitor, with an IC₅₀ of 1.94 nM. Enalaprilat can be used for the research of hypertension^[1][2][3].

IC50: 1.94 nM (ACE)^[1]

Enalaprilat (1 nM-10 μM; 24 h) attenuates the IGF-I induced neonatal rat cardiac fibroblast growth (30% reduction) in a concentration-dependent fashion, with an IC₅₀ of 90 mM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Enalaprilat (0.01%-2.9% in the eyedrop solution) shows significant intraocular pressure (IOP)-lowering effect in rabbits^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

348.39

C₁₈H₂₄N₂O₅

76420-72-9

Solid

White to off-white

O=C(O)[C@H]1N(C([C@H](C)N[C@H](C(O)=O)CCC2=CC=CC=C2)=O)CCC1

Room temperature in continental US; may vary elsewhere.

• [1]. Ceconi C, et, al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007 Dec 22;577(1-3):1-6.  [Content Brief]

  [2]. Eickels M, et, al. Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation. Br J Pharmacol. 2000 Dec;131(8):1592-6.  [Content Brief]

  [3]. Loftsson T, et, al. Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits. Acta Ophthalmol. 2010 May;88(3):337-41.  [Content Brief]